Seres Appoints Chief Commercial Officer
This article was originally published in Scrip
Seres Therapeutics Inc., a microbiome therapeutics company, has appointed Wael Hashad chief commercial officer and executive vice president. Hashad has over 25 years' experience in launching therapies for companies including Amgen, Boehringer Ingelheim and Lilly. Most recently he was vice president and regional general manager at Amgen.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.